MeiraGTx Holdings (MGTX) Receivables - Other (2019 - 2025)
MeiraGTx Holdings' (MGTX) quarterly Receivables - Other came in at $6.1 million in Q4 2025, up 47.73% YoY from $4.1 million in Q4 2024, and up 29.67% on a QoQ basis from $4.7 million in Q3 2025.
MeiraGTx Holdings (MGTX) Receivables - Other (2019 - 2025) Analysis & Trends
MeiraGTx Holdings (MGTX) has 7 years of Receivables - Other data on file, last reported at $6.1 million in Q4 2025.
- Quarterly Receivables - Other rose 47.73% year-over-year to $6.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (down 45.1% YoY) and the FY2025 annual result came in at $5.9 million, up 245.89% from the prior year.
- Receivables - Other advanced to $6.1 million in Q4 2025, from $4.7 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $36.3 million in Q1 2023 to a low of -$4.9 million in Q1 2025.
- A 5-year average of $11.7 million and a median of $12.0 million in 2021 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2022 — Receivables - Other sank 89.37% — and 2025, when it jumped 231.07%.
- Tracing MGTX's Receivables - Other over 5 years: stood at $22.4 million in 2021, then slumped by 89.37% to $2.4 million in 2022, then increased by 20.43% to $2.9 million in 2023, then surged by 43.63% to $4.1 million in 2024, then surged by 47.73% to $6.1 million in 2025.
- The last three Receivables - Other figures came in at $6.1 million (Q4 2025), $4.7 million (Q3 2025), and -$4.9 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MeiraGTx Holdings | 1.10 Bn | 1.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.08 Mn |
| Dec 31, 2025 | 6.08 Mn |
| Sep 30, 2025 | 4.69 Mn |
| Sep 30, 2025 | 4.69 Mn |
| Mar 31, 2025 | -4.85 Mn |
| Mar 31, 2025 | -4.85 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Dec 31, 2023 | 2.87 Mn |
| Dec 31, 2023 | 2.87 Mn |
| Mar 31, 2023 | 36.30 Mn |
| Mar 31, 2023 | 36.30 Mn |
| Dec 31, 2022 | 2.38 Mn |
| Dec 31, 2022 | 2.38 Mn |
| Sep 30, 2022 | 23.70 Mn |
| Sep 30, 2022 | 23.70 Mn |
| Jun 30, 2022 | 15.94 Mn |
| Jun 30, 2022 | 15.94 Mn |